S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Krystal Biotech (KRYS) Stock Forecast, Price & News

+5.45 (+10.70%)
(As of 05/13/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
186,800 shs
Average Volume
212,145 shs
Market Capitalization
$1.45 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

Krystal Biotech logo

About Krystal Biotech

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$21.40 per share


Net Income
$-69.57 million
Pretax Margin




Free Float
Market Cap
$1.45 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.20 out of 5 stars

Medical Sector

359th out of 1,403 stocks

Biological Products, Except Diagnostic Industry

57th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

Is Krystal Biotech a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech
or view top-rated stocks.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Krystal Biotech

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings results on Monday, May, 9th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.10.
View Krystal Biotech's earnings history

What price target have analysts set for KRYS?

6 analysts have issued 12 month price targets for Krystal Biotech's stock. Their forecasts range from $93.00 to $110.00. On average, they anticipate Krystal Biotech's share price to reach $101.60 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price.
View analysts' price targets for Krystal Biotech
or view top-rated stocks among Wall Street analysts.

Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the following people:
  • Mr. Krish S. Krishnan M.B.A., M.S., Founder, Chairman, Pres & CEO (Age 57, Pay $1.01M)
  • Ms. Suma M. Krishnan, Founder, COO, Pres of R&D and Director (Age 57, Pay $708.56k) (LinkedIn Profile)
  • Ms. Kathryn A. Romano, Exec. VP & Chief Accounting Officer (Age 40, Pay $452.43k)
  • Dr. Jing L. Marantz M.B.A., M.D., Ph.D., Exec. VP & Chief Bus. Officer (Age 57, Pay $46.7k)
  • Dr. Andreas C. Orth, Exec. VP & Chief Commercial Officer (Age 52, Pay $549.17k)
  • Ms. Gloria Lin, Accounting Mang.
  • Ms. Meg Dodge, VP of Investor Relations & Corp. Communications
  • Mr. David Glynn, Gen. Counsel, Commercial & Compliance
  • Mr. John Karakkal, VP of North American Sales & Marketing
  • Ms. Katherine Tuminello, HR & Office Mang.
What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.68%), Lord Abbett & CO. LLC (4.60%), Vanguard Group Inc. (4.10%), First Light Asset Management LLC (2.80%), Artal Group S.A. (1.98%) and Dimensional Fund Advisors LP (1.02%).
View institutional ownership trends for Krystal Biotech

Which major investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Verition Fund Management LLC, Cutler Group LP, Simplex Trading LLC, Citigroup Inc., Jacob Asset Management of New York LLC, Kynam Capital Management LP, and SG Americas Securities LLC.
View insider buying and selling activity for Krystal Biotech
or view top insider-selling stocks.

Which major investors are buying Krystal Biotech stock?

KRYS stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, BlackRock Inc., Jennison Associates LLC, JPMorgan Chase & Co., C WorldWide Group Holding A S, First Light Asset Management LLC, Nicholas Investment Partners LP, and Vanguard Group Inc..
View insider buying and selling activity for Krystal Biotech
or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $56.38.

How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of $1.45 billion. The company earns $-69.57 million in net income (profit) each year or ($4.37) on an earnings per share basis.

How many employees does Krystal Biotech have?

Krystal Biotech employs 119 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at (412) 586-5830 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.